{"id":55341,"date":"2023-03-30T11:04:20","date_gmt":"2023-03-30T09:04:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/"},"modified":"2023-03-30T11:04:20","modified_gmt":"2023-03-30T09:04:20","slug":"confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/","title":{"rendered":"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nCollaboration to make use of Confo\u2019s unique suite of ConfoBody<sup>\u00ae<\/sup>-enabled technologies for fragment- and structure-based drug design\n<\/li>\n<li>\nConfo to receive upfront and milestone payments totaling EUR 168M\n<\/li>\n<li>\nTiered royalties payable to Confo on net sales from resulting products\n<\/li>\n<\/ul>\n<p>GHENT, Belgium&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.confotherapeutics.com%2F&amp;esheet=53370240&amp;newsitemid=20230330005069&amp;lan=en-US&amp;anchor=Confo+Therapeutics&amp;index=1&amp;md5=e187f021caf5a79658809c0b6c25e1f0\" rel=\"nofollow noopener\" shape=\"rect\">Confo Therapeutics<\/a>, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered a collaboration agreement with Daiichi Sankyo (TSE: 4568) for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230330005069\/en\/796855\/5\/20200609_Confotherapeutics_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230330005069\/en\/796855\/21\/20200609_Confotherapeutics_Logo.jpg\"><\/a><\/p>\n<p>\nUnder the terms of the agreement, Confo will lead the discovery process deploying its GPCR platform to generate lead series of small molecule compounds. Daiichi Sankyo has an exclusive option to acquire a worldwide exclusive license for the resulting compounds and advance them towards clinical development and commercialization. Confo has the potential to receive upfront payments, development and commercial milestones totaling EUR 168M and royalties.\n<\/p>\n<p>\n\u201cDaiichi Sankyo has historically been at the forefront of leveraging innovative technologies to develop novel medicines. We are excited by this collaboration in which we will be using Confo\u2019s expertise and platform to pursue a previously undruggable GPCR target in an area of high unmet medical need,\u201d said Cedric Ververken, CEO of Confo Therapeutics. \u201cAs we expand the scope of our internal drug discovery and development efforts, we look forward to continuing to enter partnerships with leading innovators to create new therapeutic options for patients.\u201d\n<\/p>\n<p>\n<b>About Confo Therapeutics<\/b>\n<\/p>\n<p>\nConfo Therapeutics\u2019 unparalleled technology stabilizes functional conformations of GPCRs (G-protein coupled receptors), thereby enabling the discovery of chemical or biological ligands that are conformationally selective. This platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the vision of transforming therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of VIB-VUB (Vrije Universiteit Brussel) in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.\n<\/p>\n<p>\nFor more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.confotherapeutics.com%2F&amp;esheet=53370240&amp;newsitemid=20230330005069&amp;lan=en-US&amp;anchor=www.confotherapeutics.com&amp;index=2&amp;md5=4c064aec765d6b643ecd5e2379736a11\" rel=\"nofollow noopener\" shape=\"rect\">www.confotherapeutics.com<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Confo Therapeutics<\/b><br \/>Dr. Cedric Ververken, CEO<br \/>\n<br \/>+ 32 (0) 9 396 74 00<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#111;&#x3a;&#x69;n&#x66;&#111;&#x40;&#99;&#x6f;&#110;f&#x6f;&#116;&#x68;&#101;&#x72;&#97;p&#x65;&#117;&#x74;&#105;&#x63;&#115;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#105;&#x6e;f&#x6f;&#x40;&#99;&#x6f;n&#102;&#x6f;&#116;&#x68;e&#114;&#x61;p&#x65;u&#116;&#x69;c&#x73;&#x2e;&#99;&#x6f;m<\/a>\n<\/p>\n<p>\n<b>Trophic Communications<\/b><br \/>Valeria Fisher or Desmond James<br \/>\n<br \/>+ 49 175 8041816 or +49 1516 7859086<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x63;o&#110;&#x66;o&#64;&#x74;r&#111;&#x70;h&#105;&#x63;&#46;&#101;&#x75;\" rel=\"nofollow noopener\" shape=\"rect\">c&#111;&#110;&#x66;&#x6f;&#x40;&#x74;r&#111;&#112;&#104;&#x69;&#x63;&#x2e;eu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Collaboration to make use of Confo\u2019s unique suite of ConfoBody\u00ae-enabled technologies for fragment- and structure-based drug design Confo to receive upfront and milestone payments totaling EUR 168M Tiered royalties payable to Confo on net sales from resulting products GHENT, Belgium&#8211;(BUSINESS WIRE)&#8211;Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55341","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Collaboration to make use of Confo\u2019s unique suite of ConfoBody\u00ae-enabled technologies for fragment- and structure-based drug design Confo to receive upfront and milestone payments totaling EUR 168M Tiered royalties payable to Confo on net sales from resulting products GHENT, Belgium&#8211;(BUSINESS WIRE)&#8211;Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-30T09:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230330005069\/en\/796855\/21\/20200609_Confotherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases\",\"datePublished\":\"2023-03-30T09:04:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/\"},\"wordCount\":391,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005069\\\/en\\\/796855\\\/21\\\/20200609_Confotherapeutics_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/\",\"name\":\"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005069\\\/en\\\/796855\\\/21\\\/20200609_Confotherapeutics_Logo.jpg\",\"datePublished\":\"2023-03-30T09:04:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005069\\\/en\\\/796855\\\/21\\\/20200609_Confotherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005069\\\/en\\\/796855\\\/21\\\/20200609_Confotherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases - Pharma Trend","og_description":"Collaboration to make use of Confo\u2019s unique suite of ConfoBody\u00ae-enabled technologies for fragment- and structure-based drug design Confo to receive upfront and milestone payments totaling EUR 168M Tiered royalties payable to Confo on net sales from resulting products GHENT, Belgium&#8211;(BUSINESS WIRE)&#8211;Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-30T09:04:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230330005069\/en\/796855\/21\/20200609_Confotherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases","datePublished":"2023-03-30T09:04:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/"},"wordCount":391,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005069\/en\/796855\/21\/20200609_Confotherapeutics_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/","url":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/","name":"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005069\/en\/796855\/21\/20200609_Confotherapeutics_Logo.jpg","datePublished":"2023-03-30T09:04:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230330005069\/en\/796855\/21\/20200609_Confotherapeutics_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230330005069\/en\/796855\/21\/20200609_Confotherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/confo-therapeutics-enters-into-collaboration-agreement-with-daiichi-sankyo-to-discover-novel-medicines-for-cns-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55341"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55341\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}